Neurogene Therapeutics (NGNE) - Market Cap to Earnings
The market dynamics of Neurogene Inc. (NGNE) securities demonstrate the -4.30 indicator. Neurogene Inc. (NGNE) relies on its own centers in New York and Texas, which ensures stability in the development of gene therapies. The implementation of automated systems accelerates the search for effective vectors through mass screening. Meanwhile, structural flexibility is maintained by outsourcing production and trials to external contractors to minimize capital expenditures.
Comprehensive metric breakdowns and analytics for Neurogene Corp (NGNE)
- current price and projected stock value:
- market capitalization indicators:
- book value of equity indicators:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
NGNE - Net Income|Expected Net Income Neurogene Inc.|NGNE - P/E Multiple|Market Cap to Projected Earnings Neurogene Inc|NGNE - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Neurogene Inc.|NGNE - Operating profit EBITDA|Net earnings per share for the last 12 months Neurogene|NGNE - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months neurogene.com|NGNE - Earnings per share growth in current year|Projected earnings per share growth rate for next year Neurogene Inc.
Summary company analysis:NGNE (neurogene.com)
Assessing the asset quality of Neurogene Inc. (NGNE) requires an analysis of the price-to-earnings ratio. The company's trailing P/E reflects market expectations for return on investment relative to current earnings. For this gene therapy developer, this indicator measures the premium attributed to its strong reputation in treating Rett syndrome. Monitoring this metric allows for the timely identification of business overvaluation or undervalued capital potential.
Analysis of competing companies
Price to Earnings Multiple BIIB (biogen.com)|P/E Multiple NBIX|RGC - Market Cap to Earnings|Axsome Therapeutics Inc - Price to Earnings Ratio|P/E Multiple ACADIA Corp ACAD|XENE - Price to Earnings Ratio|Company Value to Net Income VKTX (vikingtherapeutics.com)|Supernus (SUPN) - Price to Earnings Ratio|Market Cap to Earnings Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - P/E Multiple|HRMY - Market Cap to Net Income Ratio|P/E Multiple BHVN|AMLX - Market Cap to Earnings|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|PRAX: Price to Earnings Multiple|Anavex Corp - P/E Multiple|Market Cap to Earnings CeriBell EEG|PRTA (prothena.com) - Price to Earnings Ratio|Alector - Company Value to Net Income|ANNX (Annexon) - P/E Multiple|Omeros Corp. (OMER) - Business Payback Period|Price to Earnings Ratio AC Immune Corp (ACIU)|Voyager Corp - Price to Earnings Multiple|P/E Multiple NMRA (Neumora Therapeutics)|SCLX - Price to Earnings Ratio|TVGN: Price to Earnings Ratio|Business Payback Period Alpha Cognition ACOG|Cognition Therapeutics, Inc. (CGTX) - Price to Earnings Ratio|Price to Earnings Multiple IKT|SAVA (Cassava Sciences, Inc.) - P/E Multiple|ASRT - Market Cap to Net Income Ratio|Price to Earnings Ratio Coya Therapeutics, Inc. (COYA)|vistagen.com - Price to Earnings Multiple|P/E Multiple OVID (Ovid Therapeutics)|Acumen Pharmaceuticals, Inc (ABOS) - Market Cap to Earnings|CRVO - Price to Earnings Ratio|ATHE (Alterity Therapeutics) - Price to Earnings Multiple|CLNN: P/E Multiple|Market Cap to Earnings PepGen (PEPG)|Price to Earnings Ratio JUNS|P/E Multiple Relmada Corp|Price to Earnings Ratio Annovis Bio, Inc. (ANVS)|GRCE (gracetx.com) - Company Value to Net Income|Price to Earnings Ratio Firefly Neuroscience AIFF|ANEW Medical (KLTO) - Market Cap to Earnings|NRSN - Price to Earnings Ratio|RVPH (Reviva Pharmaceuticals, Inc.) - Price to Earnings Multiple|MTVA: P/E Multiple|Market Cap to Earnings neuraxis.com (NRXS)|Price to Earnings Ratio HSDT|P/E Multiple Passage Bio Corp|Price to Earnings Ratio Neuphoria Therapeutics Inc. (NEUP)|NERV (Minerva) - Company Value to Net Income|Price to Earnings Ratio Athira Pharma, Inc. ATHA|addextherapeutics.com (ADXN) - Market Cap to Earnings|Alzamend - P/E Multiple|Market Cap to Net Income Ratio Cyclerion Therapeutics (CYCN)|PTIX: P/E Multiple|Market Cap to Earnings Pasithea Therapeutics Corp. (KTTA)|Price to Earnings Ratio Cortigent Inc|Price to Earnings Multiple ATXI (avenuetx.com)|P/E Multiple BCLI|CARA - Market Cap to Earnings|Chromocell Therapeutics Corporation - Price to Earnings Ratio|Company Value to Net Income ELYM|Intra-Cellular - P/E Multiple|Business Payback Period longboardpharma.com LBPH|Marinus Pharmaceuticals, Inc. (MRNS) - Price to Earnings Ratio|Price to Earnings Multiple NKGN|NRBO (NeuroBo) - P/E Multiple|Price to Earnings Ratio Sage Therapeutics Inc (SAGE)|Price to Earnings Ratio SNPX (Synaptogenix, Inc.)|Business Payback Period trevena.com|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|WENA: Price to Earnings Multiple|Cerevel - P/E Multiple
